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Background: To investigate the effect of BC1036 on health-related quality of life (QOL) in subjects with 
persistent cough. The secondary objective was to investigate the effect of BC1036 on subjective cough 
severity.
Methods: This was a randomised, multicentre, double-blind, placebo-controlled, parallel-group study in 
289 subjects with persistent cough. Subjects received BC1036 or placebo twice daily for 14 days. The primary 
endpoint comprised cough-related QOL assessed using the validated Leicester Cough Questionnaire (LCQ) 
at Day 14. Secondary endpoints comprised the LCQ scores at Day 7 and Day 28, cough severity VAS scores 
at each visit and pulmonary function tests. 
Results: At baseline, mean total LCQ score in the BC1036 group was lower (i.e., worse QOL) than placebo 
(P<0.001), indicating significant between-group heterogeneity. Mean baseline-adjusted change in LCQ score 
at Day 14 was greater for BC1036 [mean (SD) 2.4±3.5] compared to placebo [mean (SD) score 2.2±3.0], but 
did not reach statistical significance (P=0.60). Mean cough severity VAS score decreased to a greater extent 
in the BC1036 group compared to placebo, but again the results were not statistically significant (−12.2±23.28 
in BC1036 group and −11.0±21.34 in placebo group at Day 14, P=0.688). There was no significant change in 
pulmonary function measurements. The adverse event (AE) profile was similar in both groups.
Conclusions: This study showed that BC1036 was well tolerated and, although the primary endpoint did 
not achieve statistical significance, the magnitude of improvement was greater with BC1036 compared to 
placebo with respect to improving QOL and reducing cough severity.
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Introduction
At any one time, 10% of the population have a persistent 
cough (1) and acute cough is the most common reason for 
new patient consultation in primary care. Sufferers consume 
75 million doses of over-the-counter antitussive medication 
annually, totalling £98.7 million in the UK in 2014 (2,3). 
Codeine and dextromethorphan are the most commonly 
prescribed opioid-derived antitussives but their use is 
limited by unpredictable efficacy and unacceptable adverse 
events (AEs), such as somnolence, dizziness, nausea and 
constipation (4-7).
Theobromine is a methylxanthine alkaloid derivative that 
is predominant in cocoa (8,9). It has a long history of clinical 
use and has been suggested as a promising therapy for the 
treatment of persistent cough (4,10-12). BC1036 is a non-
opioid, non-narcotic, theobromine treatment and its main 
mechanisms of action are inhibition of phosphodiesterases 
and blockade of adenosine receptors. Theobromine has 
been shown to inhibit the inappropriate firing of the vagus 
nerve, which is a key feature of persistent cough. This 
peripheral mechanism of action differentiates theobromine 
from codeine and other centrally acting agents, and lessens 
its lower central nervous system AEs. Theobromine has 
been approved since 2009 in Korea for persistent cough 
under the name AnyCoughTM (developed by Ahn-Gook 
Pharmaceuticals, Seoul, South Korea). This study was carried 
out to assess the effectiveness of BC1036 for persistent cough 
in a randomised, controlled clinical trial setting. The primary 
objective was to investigate the effect of BC1036 on quality 
of life (QOL) in subjects with persistent cough. Secondary 
objectives were to investigate the effect of BC1036 on cough 
severity and objective cough reflex sensitivity. 
Methods
Study design
This was a Phase III, randomised, multicentre, double-
blind, placebo-controlled, parallel-group study conducted 
in 13 UK cough clinics and primary and secondary care 
centres between 13 July 2012 and 6 August 2013.
Subjects
Main inclusion criteria comprised males or females aged 
18–75 years with a confirmed diagnosis of persistent cough. 
This was defined as a chronic cough lasting ≥8 weeks 
at baseline or a sub-acute cough lasting ≥3 weeks at 
baseline. Subjects were required to have a Leicester 
Cough Questionnaire (LCQ)2 score of ≤17 at baseline 
and forced expiratory volume in 1 second (FEV1) ≥70% 
of predicted normal at screening. Key exclusion criteria 
were an uncontrolled intercurrent illness, treatment with 
systemic oral steroids, theophylline or theophylline-
like agents, or opiates or opioids within 7 days prior to 
randomization, significant sputum production on any 3 days 
in the screening period, or current smokers or past smokers 
who had a smoking history of >20 pack years. In addition, 
patients were excluded if any of the following applied:
 Any pulmonary abnormality on chest X-ray or 
computed tomography scan performed in the 
12 months prior to enrolment indicative of chronic 
obstructive pulmonary disorder, bronchiectasis etc.;
 Subjects diagnosed with asthma who had suffered an 
exacerbation requiring hospitalisation within 4 weeks 
prior to screening;
 Any pulmonary co-morbidity such as chronic 
obstructive pulmonary disorder, recurrent lower 
respiratory tract infections (≥2 within 12 months of 
screening) and bronchiectasis where cough suppression 
could have led to sputum retention and infection;
 Pregnant or lactating females.
With respect to all current stable regimens of over-the-
counter cough and cold remedies including antihistamines 
and decongestants, no regimen adjustments and new 
treatments could be initiated between Visit 1 and Visit 5.
Randomization
Eligible subjects were randomised to receive either BC1036 
or placebo in a 1:1 ratio using RANCODE (version 3.6). 
Study medication
Subjects were randomised to one of the following 
treatments, which were blinded by using the same capsules:
(I) BC1036 capsules: 300 mg of theobromine per 
capsule, taken orally twice daily (morning and 
evening), approximately 12 hours apart, for 14 
consecutive days. The dose selected was based 
on the pre- and post-marketing experience of 
theobromine 300 mg capsules in Korea.
(II) Matching placebo capsules, taken orally twice daily 
(morning and evening), approximately 12 hours 
apart, for 14 consecutive days.
Compliance was calculated as: (Actual number of capsules 
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used/prescribed number of capsules to be taken) ×100. A 
calculated compliance of <90% or >110% was classified as a 
major deviation.
Study schedule
Subjects attended the clinic on up to six occasions for 
consent, screening, baseline, Day 7 (±1 day), Day 14 
(±1 day), and a follow-up visit at Day 28 (±2 days). At each 
visit subjects completed the LCQ, which is a validated, 
self-reported 19-item questionnaire with a 7-point Likert 
response scale for each question. The LCQ assesses the 
impact of cough on QOL over the previous 14 days. In 
addition to the LCQ, a 100 mm cough visual analogue 
scale (VAS) was recorded at each visit, using a scale of 0= 
no cough to 100= worst cough ever. Vital signs (pulse rate, 
blood pressure and body temperature) and pulmonary 
function were also measured at each visit. Blood and 
urine samples were collected for safety clinical laboratory 
parameters at screening and Day 28, and electrocardiograms 
(ECGs) were recorded at screening and Day 14. 
Efficacy endpoints
The primary endpoint comprised cough-related QOL, 
assessed using the LCQ, with baseline-adjusted total LCQ 
score at Day 14 being the primary endpoint. The lower the 
total score, the greater the impact of the cough on various 
aspects of daily life (2).
Secondary endpoints comprised the baseline-adjusted 
LCQ scores at Day 7 and Day 28, the cough VAS scores at 
each visit, and pulmonary function tests at each visit [FEV1, 
forced vital capacity (FVC) and peak expiratory flow (PEF) 
measured using a calibrated spirometer]. 
Ethics and trial registration
This study was performed in accordance with the 
Declaration of Helsinki. This human study was approved by 
National Research Ethics Services Committee North East- 
Sunderland (approval: 11/NE/0375). All adult participants 
provided written informed consent to participate in this 
study. The clinical trial was registered on ClinicalTrials.gov 
with the registration number of NCT01656668.
Sample size justification and statistical analyses
A mean difference between BC1036 and placebo baseline-
adjusted total LCQ score of 1.3 (SD 3.2) was considered 
clinically significant (13). Based on this assumption, for a 
two-sample pooled t-test of a normal mean difference with 
a two-sided significance level of 0.05, a sample size of 129 
subjects per group was required to obtain a power of at least 
0.9 to detect a mean difference of 1.3. Assuming a drop-out 
rate of 10%, this yielded a total sample size of 144 subjects 
per treatment, i.e., 288 subjects in total.
The primary efficacy endpoint (cough-related QOL 
assessed using the LCQ) was analysed by means of an 
analysis of variance (ANOVA), including treatment and 
centre effects. Two-sided 95% confidence intervals (CIs) 
for the difference of baseline-adjusted means between 
treatment groups were calculated. Missing values for the 
LCQ score were substituted with the last observation 
carried forward (LOCF). For all other secondary variables, 
baseline-adjusted scores were analysed for Days 7, 21 and 
28 using descriptive statistics. 
All safety data obtained in this study were tabulated with 
descriptive statistics or counts and percentages depending 
on the variable. 
Results
Subject demographics
Of the 347 subjects screened, 291 were randomised at 13 
UK centres (Figure 1). Subjects had a mean age of 57 years 
(range, 19–78 years) and a mean body mass index (BMI) of 
28.3±5.3 kg/m2. Females outnumbered males by 2:1 (191 
females, 98 males) and more females were randomised to 
BC1036 (71.6% female, 28.4% male) compared to placebo 
(60.8% female, 39.2% male). There were no statistically 
significant differences between the treatment groups at 
baseline with respect to age, gender, ethnic origin, weight, 
height, BMI, or smoking history (Table 1).
Exposure to treatment
The study drug or placebo was administered to 289 
subjects. Mean compliance was 98.3% for BC1036 and 
97.5% for placebo. The mean duration of treatment was 
14 days in both groups (range 12–21 days in the BC1036 
group and 7–28 days in the placebo group).
Efficacy  
Leicester cough questionnaire
The two groups were not matched for QOL at study entry. 
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Mean total LCQ score at baseline in the BC1036 group 
was significantly lower than for placebo (i.e., had a worse 
QOL) (10.5±3.4 for BC1039 compared to 12.1±3.0 for 
placebo; P<0.001), indicating the treatment groups were not 
homogenous at baseline. 
At all assessment points during treatment and follow-
up (e.g., at days 7, 14 and 28), the mean baseline-adjusted 
score was greater for BC1036 compared to placebo, 
indicating a greater improvement in QOL compared to 
placebo treatment, but the difference between the groups 
did not reach statistical significance at any timepoint. At the 
primary endpoint of Day 14, the mean baseline-adjusted 
score LCQ was 2.4±3.5 for BC1036 and 2.2±3.0 for placebo 
(P=0.60; 95% CI: −0.98 to 0.48) (Figure 2). However, for 
both groups, mean scores were still in the moderately 
impaired range on the LCQ. 
To further investigate the significant difference between 
the treatment groups at baseline, post-hoc analyses were 
conducted in a variety of subgroups of subjects to try to 
identify whether duration of cough, the LCQ score, or 
time between screening and the start of treatment, or a 
combination of these factors, could explain this difference. 
A significant treatment effect was seen in the following 
4 subgroups at Day 7, but in all 4 groups the baseline 
difference between treatment arms was still apparent: 
 Subjects with an interval of >7 days between 
screening and Day 0 (7 days was used as the cut-off 
value because this was the washout period for prior 
medications before entry into the study);
 Subjects with an interval of >7 days between 
screening and Day 0 and baseline LCQ ≤14 (the 
LCQ of 14 was used since this is corresponds to a 
moderate cough);
 Subjects with an interval of >7 days between 
screening and Day 0 and cough ≥8 weeks;
 Subjects with an interval of >7 days between 
screening and Day 0 and cough ≥8 weeks and 
baseline LCQ ≤14.
At Day 14, no significant treatment effect was seen for 
any of the subgroups. Thus, no evidence was found in 
the post-hoc analyses explaining the significant baseline 
difference in LCQ between BC1036 and placebo.





Lost to follow-up (n=1)
Discontinued BC1036 (n=3) 
(Reason: Adverse event n=3)
Analysed (n=141) Analysed (n=148)
Lost to follow-up (n=2)
Discontinued placebo (n=6)
(Reason: adverse event n=5, other n=1)
Allocated BC1036 (n=142)
Received allocated BC1036 (n=141)
Did not receive allocated BC1036 (n=1) 
(Reason: outside of age range and did 
not have LCQ ≤17 at baseline)
Allocated placebo (n=149)
Received allocated placebo (n=148)
Did not receive allocated placebo (n=1) 
(Reason: did not have LCQ ≤17 at 
baseline)
Excluded (n=56)
Main reason for exclusion at screening 
was failure to meet all inclusion and 
inclusion criteria 
Figure 1 CONSORT flow diagram. LCQ, Leicester Cough Questionnaire.
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Table 1 Demographic details (full analysis set) 
Demographic BC1036 (N=141) Placebo (N=148) Total (N=289) P value
Age at signing informed consent 0.54*
Mean 56.6 57.6 57.1
SD 12.49 11.87 12.16
Gender 0.05‡
Male 40 (28.4) 58 (39.2) 98 (33.9)
Female 101 (71.6) 90 (60.8) 191 (66.1)
Ethnic origin 0.93‡
Caucasian 136 (96.5) 138 (93.2) 274 (94.8)
Asian 0 (0.0) 5 (3.4) 5 (1.7)
Black 4 (2.8) 4 (2.7) 8 (2.8)
Other 1 (0.7) 1 (0.7) 2 (0.7)
Height (cm)
Mean 165.51 166.47 166.00
SD 8.825 8.818 8.819
Weight (kg)
Mean 77.74 78.54 78.15
SD 16.517 16.271 16.368
BMI (kg/m2) 0.90*
Mean 28.34 28.27 28.31
SD 5.534 5.087 5.301
Smoking status 0.36‡
Non-smoker 98 (69.5) 96 (64.9) 194 (67.1)
Ex-smoker 43 (30.5) 52 (35.1) 95 (32.9)
Current 0 (0.0) 0 (0.0) 0 (0.0)
Number of pack years in ex-smokers 0.09*
Mean 9.9 7.7 8.7
SD 6.39 5.63 6.06
Cough present ≥8 weeks, n (%) 124 (87.9) 133 (89.9) 257 (88.9)
Recruited at primary care sites, n (%) 72 (51.1) 73 (49.3) 145 (50.2)
Number of pack-years not applicable for non-smokers. *, P value shows the difference between the BC1036 and placebo groups using 
analysis of variance (ANOVA) with factors treatment and centre without interaction; ‡, P value shows the difference between the BC1036 
and placebo groups using Cochran-Mantel-Haenszel test stratified by centre. SD, standard deviation; BMI, body mass index.
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Cough VAS
Subjects in the BC1036 group assessed their cough as more 
severe at baseline compared to the placebo group, although 
the difference was not statistically significant (mean of 
57.5±20.0 for BC1039 compared to 53.1±20.6 for placebo; 
P=0.066). At each timepoint during the study and at follow-
up, a greater reduction in cough severity was seen in the 
BC1036 group compared to the placebo group, but again 
the difference was not statistically significant (Table 2). 
Pulmonary function tests
At baseline, the pulmonary function tests were similar in 
the two groups: mean FEV1 was 2.7±0.8 L for BC1036 
and 2.6±0.7 L for placebo, mean FEV1 predicted (%) was 
99.0%±99.7% for BC1036 and 97.1%±96.4% for placebo, 
and mean FVC was 3.4±1.0 L for BC1036 and 3.4±0.8 L for 
placebo. There were no significant changes in lung function 
during the study period. 
Safety
During the study, 50.5% of subjects experienced 290 AEs 
(53.9% BC1036, 47.3% placebo), the majority of which 
















Figure 2 Effect of theobromine versus placebo on the change in mean (standard deviation) Leicester Cough Questionnaire (LCQ) scores.
Table 2 Baseline adjusted cough severity VAS: descriptive measures and results of ANOVA (full analysis set)













Baseline is defined as Day 0. *, P value from analysis of variance (ANOVA) with factors treatment and centre without interaction. SD, 
standard deviation; VAS, visual analogue scale.
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AEs in 59 subjects were considered drug-related (66 
BC1036, 45 placebo) (Table 3).
Discussion
There are inherent difficulties in conducting cough studies. 
Cough is a unique symptom which can be under voluntary 
control (14). Marked heterogeneity in therapeutic response 
may be seen, dependent on disease type and severity (15). 
There is a significant placebo effect (up to 85%) associated 
with over-the-counter cough medicines (14), with this 
being due to natural recovery, measures of cough severity 
declining over the course of the trial (regression of cough 
response toward the mean), the demulcent effect of 
treatment, and the effect of the sweetness of the cough 
syrup in soothing cough (14). This is further enhanced by 
expectation of effect related to advertising, brand, packaging 
and formulation (14). 
There are a number of methods used to measure 
cough frequency, intensity and severity, and reporting 
of cough is notoriously unreliable. Subjective measures 
of cough introduce considerable bias as the outcome 
relies on individual perception, which can be affected by 
environmental and psychological factors (16). Although 
cough scores using diary cards and VASs are widely used as 
an outcome measure, they are generally inaccurate because 
they rely on the motivation and vigilance of the subject, and 
do not consistently correlate with objective methods, such as 
ambulatory cough monitoring (17). Objective measurement 
of cough frequency using ambulatory electronic monitors 
is currently considered to provide greater insight into the 
reduction of cough frequency (18). At the time this study 
was conceived, no viable/validated options were available. 
However, the development of equipment to achieve this 
has been the subject of much research in recent years. 
Recent software development has led to significant progress 
in the development of automated cough detection which 
largely overcomes the issues of what constitutes “a cough” 
for the purposes of counting. This should certainly be a 
consideration for future studies.
Theobromine has been suggested as a promising therapy 
for treatment of persistent cough. It has a rapid onset, 
long duration of activity (>4 hours), is substantially more 
effective than caffeine in inhibiting cough induced by citric 
acid in the guinea-pig model, and it is at least as effective as 
theophylline and doxophylline (4). Theobromine has also 
been shown to suppress capsaicin-induced cough in humans 
with no AEs, and is considered a novel and promising 
treatment which may pave the way for a new class of 
antitussive drugs (4).
This double-blind, placebo-controlled, parallel-group 
study investigated the effect of BC1036 (theobromine) 
on the QOL of subjects with persistent cough, with the 
primary efficacy endpoint being the change from baseline in 
LCQ score on Day 14. The results showed a greater effect 
on QOL following BC1036 treatment compared to placebo, 
but the difference was small and did not reach statistical 
significance and also did not meet the pre-determined limit 
for clinical significance that was set at a total LCQ score of 
1.3 in the sample size calculation (13). However, for both 
Table 3 Adverse events
Total number of adverse events
Number of subjects/%/event count
BC1036 (N=141): 76/53.9/158 Placebo (N=148): 70/47.3/132 Total (N=289): 146/50.5/290
Most commonly reported adverse events
Headache 18/12.8/25 10/6.8/12 28/9.7/37
Nasopharyngitis 8/5.7/8 9/6.1/9 17/5.9/17
Cough (worsening) 7/5.0/8 9/6.1/9 16/5.5/17
Total number of treatment-related 
adverse events
32/22.7/65 27/18.2/45 59/20.4/110
Most commonly reported treatment-related adverse events
Headache 15/10.6/20 7/4.7/9 22/7.6/29
Nausea 4/2.8/6 2/1.4/5 6/2.1/11
Cell numbers represent the number of subjects, then the percentage of subjects with each event, and then the total number of events.
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groups, mean scores were still in the moderately impaired 
range on the LCQ. For the cough severity score, a greater 
reduction in cough severity during the study was seen in the 
BC1036 group compared to the placebo group, but again 
the difference was small and not statistically significant. 
However, a confounding factor impacting these results was 
the finding that the treatment groups were not balanced at 
baseline, with subjects in the BC1036 group having a more 
severe persistent cough that had a greater impact on QOL 
at baseline compared to subjects in the placebo group. 
Although the statistical analysis was adjusted for baseline 
severity, the difference was too great to be corrected by 
modelling alone and thus was thought to impact on the 
overall results. Despite a post-hoc subgroup analysis, no 
reason was discovered for this baseline difference. Thus, 
for future studies, stratification at randomization for cough 
severity might be considered.
The results of this study highlight the difficulties of 
conducting cough studies. However, it should be noted that 
this was the first multicentre trial conducted in persistent 
cough and the largest trial in cough at the time it was 
conducted, and much has been learnt from this trial to guide 
subsequent studies. As improvements in understanding 
cough hypersensitivity are beginning to influence 
development of new cough preparations that are effective 
on all cough types (19), so it is important that future studies 
assessing cough use validated methods that are sensitive to 
change. Future trials must be conducted for an appropriate 
length of time, and details on extent of effects, adherence, 
and AEs should be reported using clinically relevant 
outcome measures, including cough frequency, severity and 
duration (20). One consideration for future trials could be 
to use composite endpoints which can bring about statistical 
precision and encompass the several different facets of 
cough assessment (21). However, any composite endpoint 
should not be too broad, thus rendering the results clinically 
meaningless (22). The dose may also have been a factor, 
as it was based on pre- and post-marketing experience 
of theobromine 300 mg capsules (Anycough™) which is 
approved in Korea. Further investigation is needed with 
regards to the potential for genetic polymorphisms of the 
metabolising enzymes and other factors that could influence 
drug metabolism.
In conclusion, this study showed that BC1036 was well 
tolerated and, although the primary endpoint did not 
achieve statistical significance, BC1036 showed a small but 
positive effect on improving subjects’ QOL and also in 
reducing cough severity. 
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